GlycoVaxyn discovers, develops and manufactures next-generation bioconjugate vaccines.
Business Model:
Revenue: $0
Employees: 11-50
GlycoVaxyn was acquired by
GlaxoSmithKline.
The acquisition happend on 2015-02-11.
Details of the transaction were not public
Address: Grabenstrasse 3
City: Schlieren
State: zurich
Zip: 8952
Country: CH
GlycoVaxyn discovers, develops and manufactures next-generation bioconjugate vaccines.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2007 | Series A | 2 | $9.5M |
Index Ventures Sofinnova Partners Index Ventures Sofinnova Partners |
7/2006 | Seed Round | 2 | - |
Index Ventures Sofinnova Partners Index Ventures Sofinnova Partners |
3/2009 | Series B | 3 | $21.4M |
Edmond de Rothschild Private Equity Index Ventures Sofinnova Partners Edmond de Rothschild Private Equity Index Ventures Sofinnova Partners |
5/2010 | Grant | $3.4M | 3/2009 | Series B | $22M |
Edmond de Rothschild Investment Partners |
7/2006 | Seed Round | 2 | - |
Index Ventures Sofinnova Partners Index Ventures Sofinnova Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|